

Stanford



Nicholas Antonios Kalogriopoulos

Postdoctoral Scholar, Genetics

Bio

BIO

Nick's broad research interests are in developing tools and technologies for research and therapeutic applications. Nick obtained a B.S. in Genetics and Molecular Biology from the University of Wisconsin-Madison. During his undergraduate career, he trained with Dr. Paul Sondel, where he worked on preclinical testing of novel immunotherapeutic agents for the treatment of neuroblastoma. He obtained a Ph.D. in Biomedical Science with Dr. Pradipta Ghosh, elucidating the structural basis of non-canonical G protein activation by a novel protein family of Guanine Nucleotide Exchange Modulators (GEMs). As a Postdoctoral Researcher with Professor Alice Ting at Stanford University, his current research focuses on developing a new system for programmable and user-controlled cellular behaviors for immuno-oncology applications.

HONORS AND AWARDS

- F31 Ruth L. Kirschstein Predoctoral National Research Service Award, National Cancer Institute, NIH (2017-2019)
- American Society for Pharmacology and Experimental Therapeutics Travel Award, Experimental Biology (2017)
- T32 Predoctoral Training Grant in Cancer Cell Biology, National Cancer Institute, NIH (2014-2016)

PROFESSIONAL EDUCATION

- Doctor of Philosophy, University of California San Diego (2019)
- Ph.D., University of California San Diego , Biomedical Science (2019)
- B.S., University of Wisconsin-Madison , Genetics; Molecular Biology (2012)

STANFORD ADVISORS

- Alice Ting, Postdoctoral Faculty Sponsor

Publications

PUBLICATIONS

- **Structural basis for GPCR-independent activation of heterotrimeric Gi proteins.** *Proceedings of the National Academy of Sciences of the United States of America* Kalogriopoulos, N. A., Rees, S. D., Ngo, T., Kopcho, N. J., Ilatovskiy, A. V., Sun, N., Komives, E. A., Chang, G., Ghosh, P., Kufareva, I. 2019; 116 (33): 16394-16403
- **Convergence of Wnt, growth factor, and heterotrimeric G protein signals on the guanine nucleotide exchange factor Daple.** *Science signaling* Aznar, N., Ear, J., Dunkel, Y., Sun, N., Satterfield, K., He, F., Kalogriopoulos, N. A., Lopez-Sanchez, I., Ghassemian, M., Sahoo, D., Kufareva, I., Ghosh, P. 2018; 11 (519)
- **Biochemical, Biophysical and Cellular Techniques to Study the Guanine Nucleotide Exchange Factor, GIV/Girdin.** *Current protocols in chemical biology*

Ghosh, P., Aznar, N., Swanson, L., Lo, I. C., Lopez-Sanchez, I., Ear, J., Rohena, C., Kalogriopoulos, N., Joosen, L., Dunkel, Y., Sun, N., Nguyen, P., Bhandari, et al
2016; 8 (4): 265-298

- **Heterotrimeric G protein signaling via GIV/Girdin: Breaking the rules of engagement, space, and time.** *BioEssays : news and reviews in molecular, cellular and developmental biology*

Aznar, N., Kalogriopoulos, N., Midde, K. K., Ghosh, P.
2016; 38 (4): 379-93

- **Focal adhesions are foci for tyrosine-based signal transduction via GIV/Girdin and G proteins.** *Molecular biology of the cell*

Lopez-Sanchez, I., Kalogriopoulos, N., Lo, I. C., Kabir, F., Midde, K. K., Wang, H., Ghosh, P.
2015; 26 (24): 4313-24

- **Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity.** *Molecular biology of the cell*

Ma, G. S., Lopez-Sanchez, I., Aznar, N., Kalogriopoulos, N., Pedram, S., Midde, K., Ciaraldi, T. P., Henry, R. R., Ghosh, P.
2015; 26 (23): 4209-23

- **GIV/girdin binds exocyst subunit-Exo70 and regulates exocytosis of GLUT4 storage vesicles.** *Biochemical and biophysical research communications*

Lopez-Sanchez, I., Ma, G. S., Pedram, S., Kalogriopoulos, N., Ghosh, P.
2015; 468 (1-2): 287-93

- **Therapeutic effects of cell-permeant peptides that activate G proteins downstream of growth factors.** *Proceedings of the National Academy of Sciences of the United States of America*

Ma, G. S., Aznar, N., Kalogriopoulos, N., Midde, K. K., Lopez-Sanchez, I., Sato, E., Dunkel, Y., Gallo, R. L., Ghosh, P.
2015; 112 (20): E2602-10

- **Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.** *Cancer immunology, immunotherapy : CII*

Yang, R. K., Kalogriopoulos, N. A., Rakhmilevich, A. L., Ranheim, E. A., Seo, S., Kim, K., Alderson, K. L., Gan, J., Reisfeld, R. A., Gillies, S. D., Hank, J. A., Sondel, P. M.
2013; 62 (8): 1303-13

- **Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.** *Cancer immunology, immunotherapy : CII*

Rakhmilevich, A. L., Baldeshwiler, M. J., Van De Voort, T. J., Felder, M. A., Yang, R. K., Kalogriopoulos, N. A., Koslov, D. S., Van Rooijen, N., Sondel, P. M.
2012; 61 (10): 1683-97

- **Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.** *Journal of immunology (Baltimore, Md. : 1950)*

Yang, R. K., Kalogriopoulos, N. A., Rakhmilevich, A. L., Ranheim, E. A., Seo, S., Kim, K., Alderson, K. L., Gan, J., Reisfeld, R. A., Gillies, S. D., Hank, J. A., Sondel, P. M.
2012; 189 (5): 2656-64